Business
Marina Biotech Announces a New Publication on Prestalia®
Marina Biotech Announces a New Publication on Prestalia®.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n\n City of Industry, CA, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today further progress with its FDA-Approved Prestalia® hypertension drug, with the issuance of a new and independent publication on Prestalia®:  Elliott WJ and Bistrika EA (2018) Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation. Expert Opin Drug Saf. 17:207-216.\n “Substantial clinical trial experience with amlodipine or perindopril suggests that these two agents effectively lower blood pressure, and can reduce the risk of major adverse cardiovascular events, as in the Anglo-Scandinavian Cardiac Outcomes Trial.”  The author went on to say “This new formulation of perindopril arginine protects its ethyl ester, without requiring physical separation from amlodipine in a single tablet, and is less hygroscopic than perindopril erbumine. These and other attributes may make this combination an attractive addition to the antihypertensive armamentarium” “The Elliot and Bistrika publication highlights the impressive safety and efficacy profile of Prestalia, a profile which includes a reduction in cardiovascular events. It is data and analysis like this, along with the continued progress of the team at Marina that make me confident that Prestalia is well positioned for a successful launch,” said Dr. Vuong Trieu, Executive Chairman of Marina Biotech. “Additionally, new guidelines enacted by the American College of Cardiology (ACA) and the American Heart Association (AHA) that recommend that blood pressure should be treated earlier, has the potential to improve hypertension awareness and improve outcomes through lifestyle changes and treatment with drugs like Prestalia.” About Prestalia® Prestalia® contains perindopril arginine, an ACE inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension to lower blood pressure. Prestalia® may be used in patients whose blood pressure is not adequately controlled on monotherapy. Prestalia® may be used as initial therapy in patients likely to need multiple drugs to ach...